Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Automated Spot Counting in Microbiology.
Lin CP, Duan Y, Sargsyan D, Cabrera J, Livingston CM, Vogel R, Hartman J, Das M, Talloen W, Geys H, Kanoulas ED, Mohanty S. Lin CP, et al. Among authors: talloen w. IEEE/ACM Trans Comput Biol Bioinform. 2023 Nov-Dec;20(6):3703-3714. doi: 10.1109/TCBB.2023.3317339. Epub 2023 Dec 25. IEEE/ACM Trans Comput Biol Bioinform. 2023. PMID: 37725729
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U. Janssen HLA, et al. Among authors: talloen w. Gut. 2023 Jul;72(7):1385-1398. doi: 10.1136/gutjnl-2022-328041. Epub 2023 Jan 25. Gut. 2023. PMID: 36697207 Free PMC article. Clinical Trial.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Vandenbossche J, Yogaratnam J, Hillewaert V, Rasschaert F, Talloen W, Biewenga J, Snoeys J, Kakuda TN, Palmer M, Nangosyah J, Biermer M. Vandenbossche J, et al. Among authors: talloen w. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1419-1429. doi: 10.1002/cpdd.1164. Epub 2022 Sep 5. Clin Pharmacol Drug Dev. 2022. PMID: 36062869 Free PMC article. Clinical Trial.
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. Gane E, et al. Among authors: talloen w. Antivir Ther. 2022 Jun;27(3):13596535221093856. doi: 10.1177/13596535221093856. Antivir Ther. 2022. PMID: 35695169 Free article. Clinical Trial.
59 results